These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 16698850)

  • 1. Mediators and modulators of pulmonary arterial hypertension.
    Said SI
    Am J Physiol Lung Cell Mol Physiol; 2006 Oct; 291(4):L547-58. PubMed ID: 16698850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Investigation of pulmonary hypertension].
    Natali D; Simonneau G; Humbert M; Montani D
    Rev Pneumol Clin; 2008 Jun; 64(3):151-61. PubMed ID: 18656791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lysyl oxidases play a causal role in vascular remodeling in clinical and experimental pulmonary arterial hypertension.
    Nave AH; Mižíková I; Niess G; Steenbock H; Reichenberger F; Talavera ML; Veit F; Herold S; Mayer K; Vadász I; Weissmann N; Seeger W; Brinckmann J; Morty RE
    Arterioscler Thromb Vasc Biol; 2014 Jul; 34(7):1446-58. PubMed ID: 24833797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leptin signalling system as a target for pulmonary arterial hypertension therapy.
    Huertas A; Tu L; Thuillet R; Le Hiress M; Phan C; Ricard N; Nadaud S; Fadel E; Humbert M; Guignabert C
    Eur Respir J; 2015 Apr; 45(4):1066-80. PubMed ID: 25745038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pulmonary arterial hypertension.
    Raiesdana A; Loscalzo J
    Ann Med; 2006; 38(2):95-110. PubMed ID: 16581695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics of exercise capacity in female systemic lupus erythematosus associated pulmonary arterial hypertension patients.
    Pudasaini B; Yang GL; Yang C; Guo J; Yuan P; Wen-Lan Y; Zhang R; Wang L; Zhao QH; Gong SG; Jiang R; Chen TX; Wei X; Liu JM
    BMC Cardiovasc Disord; 2018 Mar; 18(1):56. PubMed ID: 29566672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selenoprotein P Promotes the Development of Pulmonary Arterial Hypertension: Possible Novel Therapeutic Target.
    Kikuchi N; Satoh K; Kurosawa R; Yaoita N; Elias-Al-Mamun M; Siddique MAH; Omura J; Satoh T; Nogi M; Sunamura S; Miyata S; Saito Y; Hoshikawa Y; Okada Y; Shimokawa H
    Circulation; 2018 Aug; 138(6):600-623. PubMed ID: 29636330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Diagnosis and classification of pulmonary hypertension].
    Montani D; Chaouat A
    Presse Med; 2010 Jun; 39 Suppl 1():1S3-15. PubMed ID: 20732615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drugs induced pulmonary arterial hypertension.
    Seferian A; Chaumais MC; Savale L; Günther S; Tubert-Bitter P; Humbert M; Montani D
    Presse Med; 2013 Sep; 42(9 Pt 2):e303-10. PubMed ID: 23972547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetics and mediators in pulmonary arterial hypertension.
    Austin ED; Loyd JE
    Clin Chest Med; 2007 Mar; 28(1):43-57, vii-viii. PubMed ID: 17338927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. P21-dependent protective effects of a carbon monoxide-releasing molecule-3 in pulmonary hypertension.
    Abid S; Houssaïni A; Mouraret N; Marcos E; Amsellem V; Wan F; Dubois-Randé JL; Derumeaux G; Boczkowski J; Motterlini R; Adnot S
    Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):304-12. PubMed ID: 24334871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism of disease: Pulmonary hypertension.
    Farber HW; Loscalzo J
    Discov Med; 2005 Feb; 5(25):80-7. PubMed ID: 20704929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in Right Ventricular Functional Changes during Treatment between Systemic Sclerosis-associated Pulmonary Arterial Hypertension and Idiopathic Pulmonary Arterial Hypertension.
    Argula RG; Karwa A; Lauer A; Gregg D; Silver RM; Feghali-Bostwick C; Schanpp LM; Egbert K; Usher BW; Ramakrishnan V; Hassoun PM; Strange C
    Ann Am Thorac Soc; 2017 May; 14(5):682-689. PubMed ID: 28282243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet-derived growth factor up-regulates Ca
    Yamamura A; Nayeem MJ; Al Mamun A; Takahashi R; Hayashi H; Sato M
    FASEB J; 2019 Jun; 33(6):7363-7374. PubMed ID: 30865840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. YC-1 attenuates hypoxia-induced pulmonary arterial hypertension in mice.
    Huh JW; Kim SY; Lee JH; Lee YS
    Pulm Pharmacol Ther; 2011 Dec; 24(6):638-46. PubMed ID: 21963997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Enhanced Ca2+-sensing receptor function in pulmonary hypertension].
    Yamamura A; Yamamura H; Yuan JX
    Yakugaku Zasshi; 2013; 133(12):1351-9. PubMed ID: 24292183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pulmonary hypertension. Pathophysiology and current concepts of medication therapy].
    Wilkens H
    Anaesthesist; 2004 Aug; 53(8):734-40. PubMed ID: 15278194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of Calpain-2 by Mediators in Pulmonary Vascular Remodeling of Pulmonary Arterial Hypertension.
    Kovacs L; Han W; Rafikov R; Bagi Z; Offermanns S; Saido TC; Black SM; Su Y
    Am J Respir Cell Mol Biol; 2016 Mar; 54(3):384-93. PubMed ID: 26248159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crucial role of ROCK2 in vascular smooth muscle cells for hypoxia-induced pulmonary hypertension in mice.
    Shimizu T; Fukumoto Y; Tanaka S; Satoh K; Ikeda S; Shimokawa H
    Arterioscler Thromb Vasc Biol; 2013 Dec; 33(12):2780-91. PubMed ID: 24135024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Definition, classification, and epidemiology of pulmonary arterial hypertension.
    Hoeper MM
    Semin Respir Crit Care Med; 2009 Aug; 30(4):369-75. PubMed ID: 19634076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.